Ciprofloxacin otic foam - Novus Therapeutics

Drug Profile

Ciprofloxacin otic foam - Novus Therapeutics

Alternative Names: Ciprofloxacin 0.3% otic foam; Foam Otic Cipro; FoamOtic Externa; OP-01 - Novus Therapeutics; OP-01 Foam

Latest Information Update: 12 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otic Pharma
  • Developer Novus Therapeutics
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Otitis externa

Most Recent Events

  • 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
  • 03 Jan 2017 Ciprofloxacin otic foam is still in phase II trials for Otitis Externa (OticPharma pipeline, January 2017)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top